Non-tuberculous mycobacteria infection: 75 cases;Akciǧerde tüberküloz dışı mikobakteri infeksiyonu: 75 olgu

Tuberkuloz ve Toraks

Volumn 60, Issue 1, 2012, Pages 20-31

  Babalik, Aylin ^a   Kuyucu, Tülin ^a   Ordu, Emine N ^a   Ernam, Dilek ^a   Partal, Mualla ^a   Köksalan, Kaya ^b  

^a Sureyyapasa Chest Diseases and Chest Surgery Training and Research Hospital   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

MGIT; NAP test; Non tuberculosis mycobacterium; Rapid test; Sputum culture

Indexed keywords

AMIKACIN; CEFOXITIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; COTRIMOXAZOLE; CYCLOSERINE; DOXYCYCLINE; ETHAMBUTOL; IMIPENEM; ISONIAZID; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TIGECYCLINE; TOBRAMYCIN; TRIMETHOPRIM;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; ATYPICAL MYCOBACTERIOSIS; BACTERIAL GROWTH; BACTERIOLOGY; COMORBIDITY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MYCOBACTERIUM; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM GORDONAE; MYCOBACTERIUM KANSASII; MYCOBACTERIUM NEONARUM; MYCOBACTERIUM SZULGAI; PATIENT COMPLIANCE; RADIOLOGY; RESPIRATORY TRACT DISEASE; TREATMENT OUTCOME; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

EID: 84862138836     PISSN: 04941373     EISSN: None     Source Type: Journal    
DOI: 10.5578/tt.2543     Document Type: Article

References (26)

1. Thomson RM, Yew WW. When and how to treat pulmonary non-tuberculous mycobacterial diseases. Respirology 2009; 14: 12-26.
2. Cassidy PM, Hedberg K, Saulson A, McNelly E, Winthrop KL. Nontuberculous mycobacterial disease prevalence and risk factors: a changing epidemiology. Clin Infect Dis 2009; 49: e124-9.
3. Martin-Casabona N, Bahrmand AR, Bennedsen J, Thomsen VO, Curcio M, Fauville-Dufaux M, et al; Spanish Group for Non-Tuberculosis Mycobacteria. Non-tuberculous mycobacteria: patterns of isolation. A multi-country retrospective survey. Int J Tuberc Lung Dis 2004; 8: 1186-93.
4. Marras TK, Chedore P, Ying AM, Jamieson F. Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997-2003. Thorax 2007; 62: 661-6.
5. Hernandez-Garduno E, Rodrigues M, Elwood RK. The incidence of pulmonary non-tuberculous mycobacteria in British Columbia, Canada. Int J Tuberc Lung Dis 2009; 13: 1086-93.
6. Khan K, Wang J, Marras TK. Nontuberculous mycobacterial sensitization in the United States: national trends over three decades. Am J Respir Crit Care Med 2007; 176: 306-13.
7. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416.
8. Horsburgh CR Jr, Caldwell MB, Simonds RJ. Epidemiology of disseminated nontuberculous mycobacterial disease in children with acquired immunodeficiency syndrome. Pediatr Infect Dis J 1993; 12: 219-22.
9. Medical Section of the American Lung Association. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Am J Respir Crit Care Med 1997; 156: 1-25.
10. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society. Management of opportunist mycobacterial infections: Joint Tuberculosis Committee Guidelines 1999. Thorax 2000; 55: 210-8.
11. Hernandez-Garduno E, Elwood RK. Demographic risk factors of pulmonary colonization by non-tuberculous mycobacteria. Int J Tuberc Lung Dis 2010; 14: 106-12.
12. Giron RM, Maiz L, Barrio I, Martinez MT, Salcedo A, Prados C. Nontuberculous mycobacterial infection in patients with cystic fibrosis: a multicenter prevalence study. Arch Bronconeumol 2008; 44: 679-84.
13. Hadjiliadis D, Adlakha A, Prakash UB. Rapidly growing mycobacterial lung infection in association with esophageal disorders. Mayo Clin Proc 1999; 74: 45-51.
14. Griffith DE, Girard WM, Wallace RJ Jr. Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients. Am Rev Respir Dis 1993; 147: 1271-8.
15. Kanathur N, Shantaveerapa HN, Byrd RP Jr, Mehta JB, Roy TM. Nontubercular mycobacterial pulmonary infection in immunocompetent men. South Med J 2001; 94: 719-23.
16. Ye JJ, Wu TS, Chiang PC, Lee MH. Factors that affect sputum conversion and treatment outcome in patients with Mycobacterium avium-intracellular complex pulmonary disease. J Microbiol Immunol Infect 2007; 40: 342-8.
17. Winthrop KL, McNelley E, Kendall B, Marshall-Olson A, Morris C, Cassidy M, et al. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. Am J Respir Crit Care Med 2010; 182: 977-82.
18. Kuroishi S, Nakamura Y, Hayakawa H, Shirai M, Nakano Y, Yasuda K, et al. Mycobacterium avium complex disease: prognostic implication of high-resolution computed tomography findings. Eur Respir J 2008; 32: 147-52.
19. Koh WJ, Kwon OJ, Jeon K, Kim TS, Lee KS, Park YK, et al. Clinical significance of nontuberculous mycobacteria isolated from respiratory specimens in Korea. Chest 2006; 129: 341-8.
20. Wittram C, Weisbrod GL. Mycobacterium avium complex lung disease in immunocompetent patients: radiography-CT correlation. Br J Radiol 2002; 75: 340-4.
21. Kim EY, Chi SY, Oh IJ, Kim KS, Kim YI, Lim SC, et al. Treatment outcome of combination therapy including clarithromycin for Mycobacterium avium complex pulmonary disease. Korean J Intern Med 2011; 26: 54-9.
22. Field SK, Cowie RL. Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine. Chest 2003; 124: 1482-6.
23. Park HK, Koh WJ, Shim TS, Kwon OJ. Clinical characteristics and treatment outcomes of Mycobacterium kansasii lung disease in Korea. Yonsei Med J 2010; 51: 552-6.
24. Wallace RJ Jr, Brown-Elliott BA, Crist CJ, Mann L, Wilson RW. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother 2002; 46: 3164-7.
25. Leber A, Marras TK. The cost of medical management of pulmonary nontuberculous mycobacterial disease in Ontario, Canada. Eur Respir J 2011; 37: 1158-652.
26. van Ingen J, Boeree MJ, de Lange WC, de Haas PE, Dekhuijzen PN, van Soolingen D. Clinical relevance of Mycobacterium szulgai in the Netherlands. Clin Infect Dis 2008; 46: 1200-5.